Provider Briefing: Amcinonide Availability in 2026

If your patients have been reporting difficulty filling Amcinonide prescriptions, their experience reflects a broader supply pattern that has affected this medication for years. While Amcinonide is not on the FDA's formal shortage list, its availability at retail pharmacies is inconsistent enough to warrant awareness and planning on the prescriber's part.

This briefing covers the current state of Amcinonide supply, prescribing considerations, cost factors, and resources you can use to help patients access their medication — or find an appropriate alternative.

Timeline: How We Got Here

Amcinonide has a relatively straightforward supply history that explains today's availability challenges:

• 1970s-1980s: Amcinonide was developed and marketed as Cyclocort by Lederle Laboratories, a division of American Cyanamid.
• 1994: American Cyanamid was acquired by Wyeth (then American Home Products), and Cyclocort continued to be marketed.
• 2009: Pfizer acquired Wyeth for $68 billion. Production of Cyclocort was subsequently discontinued.
• 2010s-present: Amcinonide has been available only as a generic, produced by a limited number of manufacturers including Taro Pharmaceuticals. The small manufacturer base has resulted in periodic supply inconsistencies.

No new manufacturers have entered the Amcinonide market in recent years, and there are no publicly announced plans to reintroduce a branded version.

Prescribing Implications

Amcinonide occupies a specific niche in the topical corticosteroid potency spectrum:

• Potency class: Group II (high potency) per the Stoughton-Cornell classification
• Concentration: 0.1% across all formulations (cream, ointment, lotion)
• Dosing: Thin film applied 2-3 times daily to affected areas
• Indications: Corticosteroid-responsive dermatoses including eczema, psoriasis, atopic dermatitis, allergic contact dermatitis, and seborrheic dermatitis

From a clinical standpoint, Amcinonide's position is not unique. Multiple other Group II and Group I agents can serve as therapeutic substitutes for most patients. However, individual patients may have responded specifically to Amcinonide, and switching carries the usual caveats around vehicle preference, patient experience, and compliance history.

For a detailed pharmacological overview, see our article on how Amcinonide works.

Current Availability Picture

The availability situation for Amcinonide in 2026 can be summarized as follows:

• FDA shortage status: Not listed on the FDA Drug Shortage Database
• Manufacturer base: Limited — fewer than 3 active generic manufacturers
• Pharmacy stocking: Inconsistent at major chains; better availability at independent and specialty pharmacies
• Mail-order availability: Generally more reliable than retail
• Formulation availability: Cream and ointment more commonly stocked than lotion

The practical reality is that many patients will need to search multiple pharmacies or use an availability tool to locate Amcinonide. This is not a crisis-level shortage, but it is a persistent access issue that affects patient care.

Cost and Access Considerations

Cost is a significant factor in Amcinonide access:

• Average retail price (without insurance): $2,100-$2,400 per 60g tube
• Best discount coupon price: ~$109 (GoodRx)
• Insurance coverage: Typically covered at Tier 2 or Tier 3 when on formulary; some plans require prior authorization or step therapy (trial of lower-potency agent first)
• No manufacturer savings program: With Cyclocort discontinued, there are no branded savings cards or copay assistance programs specific to Amcinonide

For patients without insurance or with high deductibles, the cash price can be prohibitive. Providers should proactively discuss cost and direct patients to discount programs. Our patient-facing resource on saving money on Amcinonide covers specific coupon and assistance options.

Tools and Resources for Providers

Several tools can help you and your patients navigate Amcinonide access:

Medfinder for Providers

Medfinder offers a provider-focused tool that allows you to search for pharmacy availability of specific medications, including Amcinonide. You can recommend this to patients or use it during the visit to identify a pharmacy with stock before the patient leaves your office.

Prior Authorization Support

If a patient's insurance requires prior authorization for Amcinonide, be prepared to document:

• Diagnosis and severity of the dermatologic condition
• Previous treatments tried and failed (if step therapy required)
• Clinical rationale for high-potency agent

Alternative Prescribing

When Amcinonide is unavailable, consider these alternatives:

• Fluocinonide 0.05%: Group II — closest therapeutic match, widely available
• Betamethasone Dipropionate 0.05%: Group II-III — excellent availability and affordability
• Desoximetasone 0.25%: Group II — another high-potency option
• Triamcinolone Acetonide 0.5%: Group III — slightly lower potency but extremely affordable (often under $10)

For a detailed comparison, see our clinical overview of alternatives to Amcinonide.

Looking Ahead

There are no signals that the Amcinonide supply situation will change significantly in the near term. The limited manufacturer base and low prescription volume create a structural availability issue that is unlikely to resolve without new market entrants.

For practices that frequently prescribe Amcinonide, it may be worth:

• Establishing relationships with pharmacies that reliably stock it
• Proactively discussing backup options with patients
• Using availability tools like Medfinder to verify stock before writing the prescription

Final Thoughts

Amcinonide remains a clinically effective high-potency topical corticosteroid, but its supply chain limitations require prescribers to be proactive about access. By understanding the current landscape, having alternative agents ready, and leveraging tools like Medfinder, you can help ensure your patients receive timely and effective treatment for their dermatologic conditions.

For additional clinical context, explore our articles on Amcinonide drug interactions and side effects and monitoring.